roztwór do wstrzykiwań
Sponsors
Janssen - Cilag International, Novartis Pharma AG, Wroclaw Medical University, Instytut Matki I Dziecka, Medical University Of Bialystok
Conditions
Advanced throat and larynx cancerDiffuse large B-cell lymphoma) and aggressive B-cell lymphomas (HGBCLDiffuse large B-cell lymphomas (DLBCLEGFR-mutated Advanced or Metastatic Non-small Cell Lung CancerHigh-grade B-cell lymphoma) originate from mature B-cells at various stages of terminal differentiationHodgkin lymphomaRare and ultra-rare glomerulonephritisRelapsing multiple sclerosis (RMS)
Phase 2
Subcutaneous Methotrexate, Oral Dexamethasone or Oral Montelukast for the Prevention
of Infusion Related Reaction Associated with Amivantamab, an EGFR-MET bispecific
antibody, Among Post-osimertinib Treated EGFRm NSCLC; SKIPPirr, a Phase 2 Study
Active, not recruitingCTIS2023-506578-11-00
Start: 2023-04-25Target: 60Updated: 2025-11-07
Randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of nandrolone decanoate therapy and therapy with complex physiotherapy and diet in the treatment of sarcopenia
RecruitingCTIS2024-517178-48-00
Start: 2023-03-15Target: 168Updated: 2024-10-31
A phase II efficacy and safety study of cell-free circulating tumor DNA-guided commencement of second-line treatment in patients with DLBCL/HGBCL relapse
Not yet recruitingCTIS2024-518275-64-00
Target: 340Updated: 2025-11-24
The asssessment of the efficacy of induction radiochemotherapy using low doses of ionizing radiation (iCHRTL) in the treatment of patients with advanced throat and larynx cancer
RecruitingCTIS2024-517480-23-00
Start: 2022-02-17Target: 40Updated: 2025-01-31
Phase 3
An open-label, single arm, multi-center extension study evaluating long-term safety, tolerability and effectiveness of ofatumumab in subjects with relapsing multiple sclerosis (RMS)
Active, not recruitingCTIS2023-507906-15-00
Start: 2019-01-30Target: 963Updated: 2025-11-14
Effects of calcium electroporation, electrochemotherapy, and irreversible electroporation (IRE-CaCl2, ECT and IRE) on quality of life and progression – free survival in patients with pancreatic cancer" (IREC).
RecruitingCTIS2024-512487-61-00
Start: 2022-02-10Target: 73Updated: 2024-08-09
Safety Outcomes Post Kidney Biopsy – randomized clinical Evaluation of Efficacy of Desmopressin
RecruitingCTIS2024-516270-30-00
Start: 2022-08-25Target: 454Updated: 2024-12-02
Strategy To Optimize PeriproCeduraL AnticOagulation in Structural Transseptal Interventions (STOP CLOT Trial)
Not yet recruitingCTIS2024-516376-15-00
Target: 410Updated: 2025-05-16
Efficacy and Tolerability of N-AVD compared to BrECADD in patients with advanced Hodgkin Lymphoma (N-BRAVE)
Not yet recruitingCTIS2026-525263-41-00
Target: 370Updated: 2026-05-29